Systematic Review and Meta-Analysis of Post-Progression Outcomes in ER+/HER2− Metastatic Breast Cancer after CDK4/6 Inhibitors Within Randomized Clinical Trials
Journal of Clinical Oncology（2021）
Key words
metastatic breast cancer,ER-positive/HER2-negative,endocrine therapy,CDK4/6 inhibitors,PFS2,TTC
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined